data integrity
Dr. Rachel Benett
October 1, 2026
A new hire signs the employment contract, completes the human resources orientation, and is shown to a workstation on the manufacturing floor. In a surprising number of facilities, that sequence is quietly treated as the end of onboarding. In regulatory terms it is only the beginning, and the assumption that a completed personnel file equals a qualified operator is one of the most persistent misconceptions I encounter. 21 CFR 211.25 requires that each person engaged in a manufacturing function have the education, training, and experience, or any combination thereof, to perform it, and Good Manufacturing Practice (GMP) training is the mechanism that turns a start date into a defensible qualification. When that step is skipped or postponed, the consequences are not administrative: a batch handled by an unqualified operator can be rejected, an inspector can issue an observation, and product quality can be compromised by a single step performed without understanding.
The Food and Drug Administration (FDA) and European regulators begin from the same premise. 21 CFR 211.25(a) requires training in the particular operations the employee performs and in current Good Manufacturing Practice (CGMP), including the written procedures the regulations require, conducted by qualified individuals on a continuing basis and with sufficient frequency. In the European Union, Commission Directive (EU) 2017/1572 requires that personnel receive initial and ongoing training whose effectiveness is verified, and EudraLex Volume 4, Part I, Chapter 2 (Personnel) sets out how that training should be organized according to each person’s duties. Neither framework sets a fixed calendar deadline for a new hire, yet both expect qualification to precede independent work, and both expect the evidence to exist in writing.
It is worth reading the regulation as written, because the text is more specific than many onboarding checklists assume. Section 211.25(a) requires that each person engaged in the manufacture, processing, packing, or holding of a drug product have the education, training, and experience, or any combination thereof, to perform their assigned functions. It then requires training in the particular operations the employee performs and in CGMP, including the written procedures the regulations require, conducted by qualified individuals on a continuing basis and with sufficient frequency. Section 211.25(b) applies the same qualification standard to those who supervise manufacturing, and Section 211.25(c) requires an adequate number of qualified personnel to perform and supervise the work. These are codified rules, published in the electronic Code of Federal Regulations, not general guidance.
Three features of that text deserve emphasis. Generic awareness of Good Manufacturing Practice does not satisfy the requirement if the operator has not been trained in the actual operation they are assigned to perform, which is the gap that role-based GMP training is designed to close. Second, the obligation is continuing rather than one time. A single induction session on day one does not discharge a manufacturer of its duty; competence has to be maintained and refreshed as procedures, equipment, and regulations change. Third, cGMP training explicitly includes the site’s written procedures, which means training on the standard operating procedures (SOPs) that govern a role is part of the regulatory requirement itself.
In FDA’s fiscal year 2025 inspection data for drug manufacturers, the most frequently cited observation was 21 CFR 211.22(d): procedures not in writing or not followed. Inadequate training under 211.25(a) is cited less often in its own right, but when a procedure has not been followed, the training record of the person who performed it is one of the first documents an inspector asks to see. A capable employee with no traceable record is, from the inspector’s chair, indistinguishable from an untrained one.
In my experience, a robust first month covers a recognisable set of foundations:
The distinction that matters here is between attendance and qualification. An operator who has sat through a presentation has attended; an operator who has passed an assessment and generated a dated record has been qualified. Only the second stands up when an inspector reviews the file.
If there is one lesson that recurs across pharmaceutical inspections, it is that the training itself and the evidence of training are judged as a single thing. Inadequate personnel training under 21 CFR 211.25(a) is consistently among the most frequently cited observations in FDA Form 483 inspection reports, and in a large share of those cases the underlying problem is not that the work was done badly but that the qualification behind it could not be demonstrated on paper. A capable employee with no traceable record is, from the inspector’s chair, indistinguishable from an untrained one.
This is why documentation practice and training practice cannot be separated. The way records are written, dated, corrected, and stored determines whether a training programme survives scrutiny, which is why many manufacturers pair foundational manufacturing knowledge with dedicated instruction in Good Documentation Practice. The same principle extends beyond the first month. Because 211.25 frames the obligation as continuing, sites are expected to refresh competence as guidance evolves, and periodic GMP refresher training is one common way to evidence that maintenance year on year. When an inspector opens a training file, the question is never whether the company values quality in the abstract; it is whether the record in front of them proves that a specific person was qualified to do a specific task on a specific date.
The Introduction to Good Manufacturing Practice course exists to give a new hire that defensible foundation in a single, structured, assessable programme. It was built by a team of Regulatory Affairs Experts with qualifications from Northeastern University, Boston, and it condenses the essentials of a GMP regulated environment into approximately two hours of focused study that ends in a graded examination. For a QA manager onboarding a cohort, a certified GMP training of this kind converts an inconsistent, trainer dependent induction into a repeatable process that produces the same qualification and the same record for every employee.
Course Details
Detailed Curriculum Overview
GxP Training develops its expert-led GMP training with regulatory practitioners rather than generalist content teams, so the material reflects how requirements are actually inspected rather than how they read on a slide. Every completion produces a unique, verifiable certificate that is CPD and CEU accredited and can be shared directly on a professional LinkedIn profile, which matters to individuals building a credential and to employers assembling an audit trail. Clients keep twelve months of self paced access, so a new hire can complete the essentials quickly and revisit them as questions arise, while managers can track progress across a team through built in reporting and HR tools that turn scattered completions into a single defensible record. Content is refreshed as guidance moves, and courses are SCORM (Sharable Content Object Reference Model) compatible, so an organisation can deploy them inside its own learning management system without losing the reporting that inspectors expect to see.
